Sparsentan and Irbesartan are the same class of drug, just that Sparsentan is newer than Irbesartan and works a bit better. So the Sparsentan+DMX200 combo might work a bit better than Irbesartan+DMX200.
In any case it would be to Travere's benefit if the Sparsentan-DMX200 combo could be used to treat FSGS. No reason for DMX to contribute to funding of any trials.
- Forums
- ASX - By Stock
- DXB
- Ann: Investor Briefing
Ann: Investor Briefing, page-28
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 83901 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.395 |
4 | 60000 | 0.390 |
7 | 171788 | 0.385 |
8 | 327657 | 0.380 |
4 | 209342 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 9924 | 2 |
0.410 | 103132 | 2 |
0.415 | 132474 | 5 |
0.420 | 108356 | 2 |
0.425 | 60000 | 2 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |